Nativis Research Partner to Present at COGNO Conference in Australia

A Feasibility Study Of The Nativis Voyager System In Patients With Recurrent Glioblastoma Multiforme (GBM): Interim Results Of First-In-Human Study

2017 ASCO Annual Meeting Abstract


In this prospective, multi-center trial, patients with GBM, following recurrence after receiving standard-of-care chemotherapy and/or radiotherapy were considered for the study. Patients were treated with Voyager alone or with Voyager plus concurrent chemotherapy or Avastin at the discretion of the investigator. Safety was assessed by incidence of any adverse events associated with the investigational therapy. Tumor progression at 8 weeks (2 cycles) was assessed by radiological response by local site. Patients were followed at least every 8 weeks during treatment and every 4 months thereafter.

Back to News